ZERVIATE Drug Patent Profile

When do Zerviate patents expire, and what generic alternatives are available?

Zerviate is a drug marketed by Harrow Eye and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-five patent family members in seven countries.

The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and sixty suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zerviate

A generic version of ZERVIATE was approved as cetirizine hydrochloride by PADAGIS US on June 17^th, 2008.

Summary for ZERVIATE

International Patents:	25
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	109
Patent Applications:	5,106
Drug Prices:	Drug price information for ZERVIATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZERVIATE
What excipients (inactive ingredients) are in ZERVIATE?	ZERVIATE excipients list
DailyMed Link:	ZERVIATE at DailyMed

See drug prices for ZERVIATE

Pharmacology for ZERVIATE

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

US Patents and Regulatory Information for ZERVIATE

ZERVIATE is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes
Harrow Eye	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes					Y
Harrow Eye	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes			Y
Harrow Eye	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes					Y

International Patents for ZERVIATE

See the table below for patents covering ZERVIATE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6033677
Japan	2018141022	セチリジンの眼科用製剤および使用方法 (OPHTHALMOLOGIC PREPARATION OF CETIRIZINE AND METHODS OF USE)
European Patent Office	3943069	FORMULATIONS OPHTALMIQUES DE CETIRIZINE ET PROCEDES D'UTILISATION (OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE)
European Patent Office	2547340	FORMULATIONS OPHTHALMIQUES DE CÉTIRIZINE ET LEURS MÉTHODES D'UTILISATION (OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE)
Canada	2755679

Supplementary Protection Certificates for ZERVIATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103

Market Dynamics and Financial Trajectory for Zerviate

Last updated: February 20, 2026

What is Zerviate and what is its current market position?

Zerviate (cetirizine ophthalmic solution) is an allergy treatment developed by Ioma Pharmaceuticals. It is approved by the FDA for allergic conjunctivitis. Launched in 2020, Zerviate operates in the niche of antihistamine eye drops, targeting seasonal and perennial allergic conjunctivitis.

As of 2023, Zerviate is a late entrant in the allergy eye drop market, competing primarily with broader ophthalmic antihistamines such as Pataday (olopatadine) and Zaditor (ketotifen). The drug's market share remains limited within this segment, with estimated revenues around $50 million globally in 2022.

How does Zerviate compare to competitors?

Drug	Active Ingredient	Market Launch	Indications	Estimated 2022 Revenue	Market Share (2022)
Zerviate	Cetirizine ophthalmic	2020	Allergic conjunctivitis	~$50 million	3-4% (global)
Pataday	Olopatadine	2009	Allergic conjunctivitis, ocular allergy	~$500 million	30%
Zaditor	Ketotifen fumarate	1996	Allergic conjunctivitis, ocular allergy	~$200 million	12%

Zerviate's sales trail significantly behind established OTC and prescription antihistamines. It holds a small segment mainly due to brand recognition and formulary access.

What market trends influence Zerviate's prospects?

Rising prevalence of allergic conjunctivitis

• Global allergic rhinitis affects approximately 23% of the population [1].
• Allergic conjunctivitis often co-occurs, increasing demand for effective treatments.
• Weather changes, urban pollution, and climate shifts contribute to higher incidence.

Growth in prescription ophthalmic products

• The ophthalmic drug market expanded at a CAGR of 4% from 2018 to 2022.
• Prescription antihistamines account for roughly 65% of the allergy eye drop market [2].

Challenges in market penetration

• OTC products dominate the allergy eye market.
• Established drugs, especially OTC brands like Zaditor, have strong customer loyalty.
• Payor and formulary restrictions limit new entrant sales.

What is the financial trajectory forecast?

Revenue projections

• Current revenue (~$50 million in 2022) is projected to grow at a CAGR of approximately 3% over the next five years.
• If Zerviate gains 5% additional market share annually within its segment, revenues could reach ~$75 million by 2027.

Cost considerations

• Marketing and education will be pivotal to increase physician awareness.
• R&D expenses have been minimal post-launch, focusing instead on labeling updates and formulations.
• Price negotiations with payors will influence profitability. Zerviate is priced at a premium relative to OTC options, averaging around $40 per 10 mL bottle.

Investment factors

• Expansion into new markets (e.g., Europe, Asia) could double revenue prospects if approved.
• Patent exclusivity lasts until 2030, providing a protected window for market growth.
• Market entry barriers include formulary acceptance and clinician awareness.

What regulatory and policy developments could impact Zerviate?

• Expansion for broader indications (e.g., ocular itch from other causes) may enhance sales.
• Changes in prescription reimbursement policies could incentivize physicians to prescribe branded products.
• Public health policies advancing OTC options might challenge prescription sales.

Key Takeaways

• Zerviate occupies a small niche within the allergy eye drop market, with limited market share compared to established products.
• Market growth drivers include the increasing prevalence of allergic conjunctivitis and rising ophthalmic drug sales.
• Challenges include market saturation, OTC competition, and formulary barriers.
• Financial prospects depend on market penetration efforts, geographic expansion, and evolving regulatory policies.
• Revenue is forecasted to grow modestly, reaching around $75 million by 2027 if growth strategies succeed.

FAQs

1. What barriers does Zerviate face in increasing its market share?

It encounters competing OTC products with strong brand loyalty, formulary restrictions limiting prescription access, and limited clinician awareness compared to established antihistamines.

2. How does patent protection influence Zerviate’s growth?

Patents lasting into 2030 restrict generic competition, allowing pricing control and market exclusivity during this period.

3. Are there upcoming regulatory changes that could benefit Zerviate?

Potential expansion of approved indications and new market authorizations in Europe or Asia could drive growth, contingent on regulatory approval timing and market access strategies.

4. How do the cost and pricing of Zerviate compare to OTC alternatives?

Zerviate’s pricing (~$40 per 10 mL bottle) is higher than OTC options like Zaditor (~$10), impacting market adoption outside prescription settings.

5. What strategic actions could enhance Zerviate’s market stand?

Investing in physician education, increasing formulary coverage, expanding geographic reach, and pursuing additional indications could improve sales.

---

References

[1] Bousquet, J., et al. (2021). Global prevalence of allergic rhinitis. Journal of Allergy and Clinical Immunology, 147(4), 1239-1244.

[2] IQVIA. (2022). Ophthalmic drug market insights. IQVIA Market Reports.